


F1 G.1



SUMMARY OF Stx2 Hu mAb ACTIVITY
AGAINST CLINICAL Stx2 AND Stx2 VARIANTS






FIG.2

FIG.3



AVERAGE SURVIVAL OF MICE GIVEN 5,10,20,35 OR 50 µg OF Stx2-SPECIFIC Hu-mAbs FOLLOWED 18 HOURS LATER WITH 25ng Stx2



IN VITRO NEUTRALIZATION OF Stx2 AND Stx2c
(PRODUCED BY CLINICAL STEC ISOLATES)
BY Stx 2 - SPECIFIC Hu-mAb





FIG.5

5H8=anti-A+B subunit
6G3=anti-A+B subunit
2F10=anti-A subunit
3E9=anti-A subunit
5C12=anti-A subunit

AVERAGE DAYS OF SURVIVAL OF MICE GIVEN 30 μ g
Hu-mAb 2F10, 3E9, 5C12, 5H8, OR 6G3 FOLLOWED 18 HOURS LATER
WITH Stx2c CONTAINING CULTURE SUPERNATANT



Stx2c PRODUCING E.coli ISOLATE (95-8061)

FIG. 6